600267 海正药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)5.367-1.1526.3566.9656.442
总资产报酬率 ROA (%)2.520-0.5122.5632.4201.971
投入资产回报率 ROIC (%)3.112-0.6363.1963.0602.602

边际利润分析
销售毛利率 (%)39.37240.33841.85540.78643.273
营业利润率 (%)9.3080.8625.6705.7686.842
息税前利润/营业总收入 (%)10.6441.0497.8618.03711.596
净利润/营业总收入 (%)8.278-0.9354.0814.2076.369

收益指标分析
经营活动净收益/利润总额(%)69.196-287.995114.28199.97765.556
价值变动净收益/利润总额(%)35.030-80.049-12.03512.7233.890
营业外收支净额/利润总额(%)-0.516207.9360.138-8.67414.077

偿债能力分析
流动比率 (X)0.8710.9660.8990.7240.698
速动比率 (X)0.6210.6690.6300.4940.454
资产负债率 (%)50.58952.59655.63862.08660.419
带息债务/全部投入资本 (%)38.26441.74543.84350.53052.343
股东权益/带息债务 (%)156.834134.380124.12991.79979.345
股东权益/负债合计 (%)94.79487.45877.33060.71552.992
利息保障倍数 (X)7.6950.5683.6012.9453.192

营运能力分析
应收账款周转天数 (天)68.00175.87168.01455.24852.666
存货周转天数 (天)105.077112.587101.257114.909126.529